Journal
PHARMACEUTICALS
Volume 14, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/ph14050443
Keywords
interleukin-7; cytokine receptor; JAK kinases; signaling; lymphocyte development; lymphoid malignancy; acute lymphoblastic leukemia; kinase inhibitor; targeted treatment
Categories
Funding
- VIB
- KU Leuven
- Stichting Tegen Kanker
- Kom op Tegen Kanker
Ask authors/readers for more resources
The cytokine interleukin-7 (IL-7) and its receptor play critical roles in lymphoid cell development, with abnormalities in the IL-7 signaling pathway being associated with malignant transformation of lymphocytes. Mutations in components of the IL-7 pathway, including IL7R, IL2RG, JAK1, JAK3, STAT5B, PTPN2, PTPRC, and DNM2 genes, are frequently found in T-cell leukemia.
The cytokine interleukin-7 (IL-7) and its receptor are critical for lymphoid cell development. The loss of IL-7 signaling causes severe combined immunodeficiency, whereas gain-of-function alterations in the pathway contribute to malignant transformation of lymphocytes. Binding of IL-7 to the IL-7 receptor results in the activation of the JAK-STAT, PI3K-AKT and Ras-MAPK pathways, each contributing to survival, cell cycle progression, proliferation and differentiation. Here, we discuss the role of deregulated IL-7 signaling in lymphoid malignancies of B- and T-cell origin. Especially in T-cell leukemia, more specifically in T-cell acute lymphoblastic leukemia and T-cell prolymphocytic leukemia, a high frequency of mutations in components of the IL-7 signaling pathway are found, including alterations in IL7R, IL2RG, JAK1, JAK3, STAT5B, PTPN2, PTPRC and DNM2 genes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available